- Home
- NVG vs RCUS Comparison
NVG vs RCUS Comparison
Compare NVG & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVG | RCUS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NVG | RCUS |
|---|---|---|
| Price | $12.40 | $24.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.90 |
| AVG Volume (30 Days) | 569.6K | ★ 857.7K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.50 | $7.92 |
| 52 Week High | $13.59 | $28.72 |
Technical Indicators
Market Signals| Indicator | NVG | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 51.01 |
| Support Level | $12.37 | $23.91 |
| Resistance Level | $12.44 | $24.33 |
| Average True Range (ATR) | 0.10 | 1.18 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 45.38 | 46.46 |
Price Performance
Historical ComparisonAbout NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.